DNA vaccination against bcr-abl-positive cells in mice

被引:12
作者
Lucansky, Vincent [1 ]
Sobotkova, Eva [1 ]
Tachezy, Ruth [1 ]
Duskova, Martina [1 ]
Vonka, Vladimir [1 ]
机构
[1] Inst Hematol & Blood Transfus, Dept Expt Virol, CR-12820 Prague 2, Czech Republic
关键词
CML; bcr-abl-transformed mouse cells; DNA vaccines; CHRONIC MYELOGENOUS LEUKEMIA; LOADED DENDRITIC CELLS; IMATINIB MESYLATE; FUSION PEPTIDES; IMMUNOTHERAPY; ONCOGENE; IMMUNOGENICITY; TRANSFORMATION; MECHANISMS; DISEASE;
D O I
10.3892/ijo_00000408
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A series of DNA vaccines based on the bcr-abl fusion gene were developed and tested in mice. Two mouse (BALB/c) bcr-abl-transformed cell lines, B210 and 12131, which both expressed p210(bcr-abl) and were oncogenic for syngeneic animals but differed in some other respects, were used as a model system. In the first series of experiments, plasmids carrying either the complete bcr-abl fusion gene or a fragment thereof coding for a 25-amino acid-long junction zone (bcr-abl25aa) linked with genes coding for a variety of immunostimulatory factors were used as the DNA vaccines. A plasmid carrying the complete bcr-abl gene was capable of inducing protection against challenge with either B210 or 12B1 cells. However, the DNA vaccines based on the gene fragment coding for p25aa(bcr-abl) did not induce significant protection. To localize the immunizing epitopes on the p210(bcr-abl) protein, the whole fusion gene was split into nine overlapping fragments and these, individually or in various combinations, were used for immunization. Although none of the vaccines based on any single fragment provided potent protection, some combinations of these fragment-based vaccines were capable of eliciting protection comparable to that seen after immunization with the whole-gene vaccine. Surprisingly, a mixture of six fragment-vaccines was more immunogenic than the complete set of fragment DNA vaccines. To analyze this phenomenon, the three fragments missing from the hexavaccine were either individually or in various combinations mixed with the hexavaccine. The results obtained suggested that the product of the fragment coding for 197 amino acids forming the N-terminal of the BCR protein was involved in the decreased immunogenicity. However, further experiments are needed to clarify the point. Additional experiments revealed that all the important epitopes were located in the ABL portion of the p210(bcr-abl) protein. The livers, spleens and bone marrows of the successfully immunized animals were tested for the presence of bcr-abl-positive cells by RT-PCR. The results were negative, this suggesting that these animals were free of any residual disease.
引用
收藏
页码:941 / 951
页数:11
相关论文
共 50 条
  • [21] Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells
    Chatain, N.
    Ziegler, P.
    Fahrenkamp, D.
    Jost, E.
    Moriggl, R.
    Schmitz-Van de Leur, H.
    Mueller-Newen, G.
    ONCOGENE, 2013, 32 (31) : 3587 - 3597
  • [22] A bis-pyridinium fullerene derivative induces apoptosis through the generation of ROS in BCR-ABL-positive leukemia cells
    Sumi, Kazuya
    Tago, Kenji
    Nakazawa, Yosuke
    Takahashi, Kyoko
    Ohe, Tomoyuki
    Mashino, Tadahiko
    Funakoshi-Tago, Megumi
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2022, 916
  • [23] Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants
    A Janowska-Wieczorek
    M Majka
    L Marquez-Curtis
    JA Wertheim
    AR Turner
    MZ Ratajczak
    Leukemia, 2002, 16 : 1160 - 1166
  • [24] Nitric oxide induces the apoptosis of human BCR-ABL-positive myeloid leukemia cells: evidence for the chelation of intracellular iron
    H Ferry-Dumazet
    M Mamani-Matsuda
    M Dupouy
    F Belloc
    D Thiolat
    G Marit
    M Arock
    J Reiffers
    MD Mossalayi
    Leukemia, 2002, 16 : 708 - 715
  • [25] Nitric oxide induces the apoptosis of human BCR-ABL-positive myeloid leukemia cells: evidence for the chelation of intracellular iron
    Ferry-Dumazet, H
    Mamani-Matsuda, M
    Dupouy, M
    Belloc, F
    Thiolat, D
    Marit, G
    Arock, M
    Reiffers, J
    Mossalayi, MD
    LEUKEMIA, 2002, 16 (04) : 708 - 715
  • [26] Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants
    Janowska-Wieczorek, A
    Majka, M
    Marquez-Curtis, L
    Wertheim, JA
    Turner, AR
    Ratajczak, MZ
    LEUKEMIA, 2002, 16 (06) : 1160 - 1166
  • [27] Successful Treatment with Imatinib Mesylate in a Case of Minor BCR-ABL-Positive Acute Myelogenous Leukemia
    Katsuro Ito
    Kazunori Tominaga
    Toshiya Suzuki
    Itsuro Jinnai
    Masami Bessho
    International Journal of Hematology, 2005, 81 : 242 - 245
  • [28] BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features
    Neuendorff, Nina Rosa
    Burmeister, Thomas
    Doerken, Bernd
    Westermann, Joerg
    ANNALS OF HEMATOLOGY, 2016, 95 (08) : 1211 - 1221
  • [29] Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia
    Ito, K
    Tominaga, K
    Suzuki, T
    Jinnai, I
    Bessho, M
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2005, 81 (03) : 242 - 245
  • [30] Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies
    Weisberg, Ellen
    Nonami, Atsushi
    Griffin, James D.
    ARCHIVES OF TOXICOLOGY, 2014, 88 (12) : 2233 - 2242